Urology Practice Management - June 2016, Vol 5, No 3

Testosterone Replacement Does Not Increase Risk  for Prostate Cancer, Cardiovascular Disease

The study examined the association between testosterone replacement and prostate cancer using the National Prostate Cancer Register and the Prescribed Drug Register, which identified 38,570 men with a prostate cancer between 2009 and 2012, and 192,838 men without prostate cancer in the control group.

Read More ›

Efficiency in the Urology Practice, Part 2: When the Patient Arrives at Your Office
This article looks to enhance practice management efficiencies when patients arrive at your office. Read More ›

As we move into another year, it is important now more than ever for medical practices to ensure that they have a robust Health Insurance Portability and Accountability Act (HIPAA) compliance program in place. In 2009, the Office for Civil Rights (OCR) was appointed as the enforcement arm for HIPAA, and with that appointment came a mandate by Congress to begin auditing entities that fall under the HIPAA rules.

Read More ›

The study included 2 main comparisons of adjuvant chemoradiotherapy versus radiation and adjuvant chemoradiotherapy versus chemotherapy alone. The 3-year disease-free survival rate was 68% for adjuvant chemoradiotherapy versus 63% for radiation alone, but this 5% difference was not statistically significant. The 3-year disease-free survival rate in the second comparison was 68% for chemoradiotherapy versus 56% for chemotherapy alone, a numerical trend toward improved survival with chemoradiotherapy.

Read More ›

On May 27, 2016, the FDA approved fluciclovine F18 (Axumin; Blue Earth Diagnostics) injection, a radioactive diagnostic imaging agent used to detect recurrent prostate cancer.

Read More ›

On May 18, 2016, the FDA granted accelerated approval to atezolizumab (Tecentriq; Genentech) for the treatment of patients with locally advanced or me­tastatic urothelial carcinoma who have disease progression during or after platinum-containing chemotherapy, or for those who have had disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Read More ›

Because physicians are personally responsible for their own professional negligence or malpractice, regardless of whether they practice with or without a legal entity, what is the benefit of having one? Although a legal entity does not provide any liability protection from professional negligence or malpractice, it does shield you from liabilities that result from the actions of others. Read More ›

Strategies for Payer–Provider Contract Negotiation: Preparation and Data Are Crucial

Successful contract negotiation comprises a process involving a realistic self-assessment, an evaluation of your counterpart, and the development of a negotiating strategy, according to John M. Murphy, MD, MBA, Chief Executive Officer and Chief Medical Officer, Delaware Valley Urology, Mount Laurel, NJ.

Read More ›

Urology Practice Management logo
Subscribe to Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.

UPM e-Newsletter
UPM print publication